Celcuity, Inc. (NASDAQ:CELC) Stock Now Rated “Moderate Buy” by Sell-Side Analysts

Celcuity, Inc. (NASDAQ:CELC) has been given a consensus recommendation of “Moderate Buy” by the twelve analysts that are presently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation and eleven have assigned a buy recommendation to the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $154.25.

Several research analysts recently weighed in on CELC shares. Guggenheim increased their price objective on Celcuity from $165.00 to $175.00 and gave the stock a “buy” rating in a research report on Monday, August 17th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Celcuity in a research note on Tuesday, September 1st. Craig Hallum reiterated a “buy” rating and set a $178.00 price target on shares of Celcuity in a report on Wednesday, July 15th. Citigroup restated a “market outperform” rating on shares of Celcuity in a report on Monday, August 17th. Finally, JPMorgan Chase & Co. assumed coverage on shares of Celcuity in a research report on Thursday, September 17th. They issued an “overweight” rating and a $157.00 target price on the stock.

Celcuity Stock Performance

NASDAQ:CELC opened at $71.25 on Friday. The company’s 50-day moving average is $87.13 and its two-hundred day moving average is $102.27. Celcuity has a 1-year low of $45.03 and a 1-year high of $151.02. The company has a debt-to-equity ratio of 6.04, a current ratio of 8.93 and a quick ratio of 8.93. The firm has a market capitalization of $3.49 billion, a price-to-earnings ratio of -16.57 and a beta of 0.10.

Celcuity (NASDAQ:CELC) last announced its quarterly earnings results on Thursday, August 13th. The company reported ($1.44) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.16) by ($0.28). Analysts forecast that Celcuity will post -4.82 EPS for the current year.

Institutional Trading of Celcuity

Several institutional investors have recently added to or reduced their stakes in CELC. PNC Financial Services Group Inc. boosted its stake in Celcuity by 20.1% in the first quarter. PNC Financial Services Group Inc. now owns 514 shares of the company’s stock valued at $59,000 after acquiring an additional 86 shares in the last quarter. EverSource Wealth Advisors LLC increased its position in shares of Celcuity by 15.1% during the second quarter. EverSource Wealth Advisors LLC now owns 944 shares of the company’s stock worth $99,000 after purchasing an additional 124 shares in the last quarter. Intech Investment Management LLC lifted its holdings in shares of Celcuity by 1.4% in the 4th quarter. Intech Investment Management LLC now owns 12,983 shares of the company’s stock valued at $1,295,000 after purchasing an additional 183 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in shares of Celcuity by 1.0% in the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 31,092 shares of the company’s stock valued at $3,253,000 after purchasing an additional 297 shares during the last quarter. Finally, Parallel Advisors LLC acquired a new stake in shares of Celcuity in the 1st quarter valued at about $38,000. Institutional investors and hedge funds own 63.33% of the company’s stock.

About Celcuity

Celcuity, Inc is a clinical-stage biotechnology company that develops functional diagnostic tests designed to help identify patients who may benefit from targeted cancer therapies. The company’s technology is intended to measure the activity of cellular signaling networks in living tumor cells, rather than relying solely on the presence or absence of individual biomarkers.

Celcuity’s proprietary CELsignia platform analyzes patient tumor samples to identify abnormal signaling activity associated with cancer growth and treatment response.